Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 19, 2019 / 04:30PM GMT
Release Date Price: $97.93 (+5.61%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

My name is Paul Matteis. I'm a Biotech Analyst at Stifel. Happy to have Josh Brodsky, who runs Investor Relations at Alnylam, give us a presentation on Alnylam's progress. I think it's just going to be a presentation day because you guys have the R&D Day Friday, right? So Josh, you want to take it away?

Joshua Brodsky
Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications

Great. Okay. Thanks so much, Paul. Pleasure to be here. Thanks to you and the conference organizers for inviting Alnylam to participate. Good morning, everyone. My name is Josh Brodsky, I'm Director of Investor Relations and Corporate Communications at Alnylam. I will, of course, be making some forward-looking statements, and so I encourage you to review our most recent SEC filings for a more complete discussion of our risk factors.

Now as you may know, Alnylam has been the leader in advancing RNAi therapeutics as a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot